Acquisitions /mergers/joint-ventures Cigna rejects Anthem’s offer US Health insurer Cigna sharply rejected Anthem’s bid proposal worth nearly $54 billion including debt in saying the terms of the bid are inadequate and “woefully skewed in favor of Anthem’s shareholders. Nothing of this size and scale has been attempted in our sector," the Cigna officials said of the […]

Acquisitions /mergers/joint-ventures Teva-Mylan-Perrigo: An ongoing process This week Abbott has indicated that it intends to vote its 14.5% stake in Mylan, acquired in late February through a 5.3 billion stock swap, in favor of a Perrigo buy. But OTC-focused Perrigo has so far repeatedly turned down Mylan’s offers indicating that they “substantially” undervalue the company. […]

Acquisitions /mergers/joint-ventures Actelion rebuffs Shire’s offer Shire’s offer to acquire Actelion (Basel-Allschwil, Switzerland) values the Swiss company at $18.9 billion or about 160 Swiss franc a share. “Actelion board’s alleged unwillingness to open the books at 160 francs may suggest their expectations are far higher,” according to UBS AG Guillaume van Renterghem. “We believe Shire […]

  Editor’s Corner (June 2015)       The Breakthrough of Immunotherapy   The success of immunotherapy and in particular of immune-oncology therapies is confirmed almost every day with new and sometimes spectacular clinical results and outcomes showing the value of this approach. Immunotherapy treatment uses the body’s immune system to attack cancerous cells and […]

Acquisitions /mergers/joint-ventures The Teva-Mylan-Perrigo saga goes on Perrigo who has indicated it was not enthusiastic about being acquired by Mylan, claiming the offer substantially undervalued the company, announced the acquisition of a portfolio of OTC brands from GlaxoSmithKline for an undisclosed amount. Nearly six weeks after Teva publicly expressed interest in acquiring generics rival, Mylan […]

Acquisitions /mergers/joint-ventures Chinese consortium buys US Ambrx A consortium of Chinese healthcare business and funds will acquire US biotech Ambrx (San Diego, CA, USA) which abandoned its IPO last year. China Everbright’s healthcare fund, Shanghai Fosun Pharmaceutical Group, HOPU Investments and WuXi Pharma Tech have announced the deal without providing financial details. The acquisition will […]